Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | PAFAH1B2 | P68402 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7943945 | 0.86 | KMT2A (0.39) | GAANOTUMPAFAH1B2 | |
| SCHEMBL5753883 | 0.83 | KMT2A (0.41) | GAANOTUM | |
| SCHEMBL5756766 | 0.82 | HIF1A (0.40) | GAANOTUMPTGER1 | |
| SCHEMBL5755180 | 0.70 | FAAH (0.38) | GAANOTUM | |
| SCHEMBL7950977 | 0.70 | AGER (0.37) | GAAPTGER1 | |
| SCHEMBL8073611 | 0.70 | NLRP3 (0.42) | NOTUMPTGER1 | |
| SCHEMBL7957026 | 0.70 | P2RX1 (0.46) | NOTUM | |
| SCHEMBL5752890 | 0.70 | KMT2A (0.39) | GAANOTUMPAFAH1B2 | |
| SCHEMBL5754958 | 0.68 | NR1H2 (0.40) | GAANOTUM | |
| SCHEMBL5752911 | 0.68 | KMT2A (0.41) | GAANOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5869509-A | TREAT DISORDERS RESPONSIVE TO OPENERS OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-09 | — | — | US | claimed |
| US-20210393596-A1 | DRUG FOR TREATING TINNITUS | SCOTT, LUISA LYNN | 2021-12-23 | — | — | US | disclosed |
| US-6271249-B1 | Diphenyl imidazoles as potassium channel modulators | BRISTOL-MYERS SQUIBB COMPANY | 2001-08-07 | — | — | US | disclosed |
| US-6077861-A | MODULATORS OF THE LARGE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM (BK) CHANNELS, THEREFORE, USEFUL IN THE TREATMENT OF ISCHEMIC STROKE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-06-20 | — | — | US | disclosed |
| US-5869509-A | TREAT DISORDERS RESPONSIVE TO OPENERS OF THE LARGE CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210393596-A1 | DRUG FOR TREATING TINNITUS | CHAT, SLC18A2, TRPV1 | GAA 1273/4885NOTUM 1433/4885PAFAH1B2 2727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.